blogs

Careers

clients

Case Studies

Offices

About Us

pages

people

posts

staffs

testimonials

Home - Whistleblower Attorneys

core/heading

Johnson &amp; Johnson (JNJ) will pay more than $1 billion to the U.S. and most states to resolve a civil investigation into marketing of the antipsychotic Risperdal, according to people familiar with the matter.

core/paragraph

J&amp;J, the world’s largest health products company, reached an agreement last week with the U.S. attorney in Philadelphia, according to the people, who weren’t authorized to speak about the matter. Negotiations over a possible criminal plea are still under way, they said.

The U.S. government has been investigating Risperdal sales practices since 2004, including allegations the company marketed the drug for unapproved uses, J&amp;J has said in Securities and Exchange Commission filings (JNJ). The company said it has been in negotiations with the U.S. to settle the investigation.

To read the complete article, click here.

core/button

core/buttons

Johnson & Johnson Said to Agree to Pay $1 Billion in Risperdal Marketing Probe

News